Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of NEDD9 regulated genes in VCaP prostate cancer cells

ABSTRACT: Identification of NEDD9 regulated genes in VCaP prostate cancer cells

PROVIDER: PRJNA691065 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genes regulated by soluble guanylyl cyclase in VCaP prostate cancer cells

Project description:The aberrant activation of the ERG oncogenic pathway due to TMPRSS2-ERG gene fusions is the major driver of prostate cancer initiation and progression. We identified the alpha1 and beta1 subunits of soluble guanylyl cyclase (GUCY1A1, GUCY1B1) as major ERG-regulated genes in prostate cancer cells. Soluble guanylyl cyclase (sGC) is the major mediator of nitric oxide signaling in cells that, upon nitric oxide binding, catalyzes the synthesis of cGMP and subsequently activates PKG. We showed in ERG-positive PCa cells (VCaP) that cGMP synthesis was significantly elevated by ERG, leading to increased PKG activity and cell proliferation. To further understand the functions of sGC-cGMP pathway in prostate cancer cells, we performed RNA-seq analyses in VCaP cells to identify genes that are regulated by sGC.

2018-05-22 | GSE114738 | GEO

Genes regulated by soluble guanylyl cyclase in VCaP prostate cancer cells

Project description:Genes regulated by soluble guanylyl cyclase in VCaP prostate cancer cells

| PRJNA472401 | ENA

Identification of NEDD9 regulated genes in VCaP prostate cancer cells

Project description:NEDD9 gene (Neural precursor Expressed, Developmentally Down-regulated 9) encodes a member of the Cas family of signaling transduction molecules, which is a non-catalytic focal adhesion protein phosphorylated by FAK and Src and functions as a signaling hub to regulate downstream signaling, such as the AKT pathway. In cancers, NEDD9 regulates cell migration, epithelial-mesenchymal transition (EMT), invasion, and metastasis. Gene amplification of NEDD9 is commonly found in the advanced metastatic castration-resistant PCa (~3%) and neuroendocrine PCa (~15%), suggesting NEDD9 may play an important role in PCa progression. In order to characterize the global functions of NEDD9 in PCa cells, we performed RNA-seq analyses in VCaP cells (containing NEDD9 gene amplification) stably infected with shRNA against NEDD9 or non-targeting control (NTC).

2021-01-11 | GSE164531 | GEO

AR binding in prostate cancer cell lines VCaP and VCS2

Project description:This SuperSeries is composed of the following subset Series: GSE32344: Expression profilling of prostate cancer VCaP and VCS2 cells GSE32345: Genome-wide maps of AR binding in prostate cancer cell lines VCaP and VCS2 Refer to individual Series

2012-02-01 | E-GEOD-32356 | biostudies-arrayexpress

ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes

Project description:Libraries of single-stranded oligodeoxynucleotides (ssODNs) can be enriched for sequences that specifically bind molecules on naïve complex biological samples like cells or tissues. Depending on the enrichment strategy, the ssODNs can identify molecules specifically associated with a defined biological condition, for example a pathological phenotype, and thus are potentially useful for biomarker discovery. We performed ADAPT, a variant of SELEX, on exosomes secreted by VCaP prostate cancer cells. A library of ~1011 ssODNs was enriched for those that bind to VCaP exosomes and discriminate them from exosomes derived from LNCaP prostate cancer cells. Next-generation sequencing (NGS) identified the best discriminating ssODNs, nine of which were resynthesized and their discriminatory ability confirmed by qPCR. Affinity purification with one of the sequences (Sequence 7) combined with LC-MS/MS identified its molecular target complex, whereof most proteins are part of or associated with the multiprotein ESCRT complex participating in exosome biogenesis. Within this complex, YBX1 was identified as the directly bound target protein. ADAPT thus is able to differentiate exosomes from cancer cell subtypes from the same lineage. The composition of ESCRT complexes in exosomes from VCaP versus LNCaP cells might constitute a discriminatory element between these prostate cancer subtypes.

2020-01-13 | PXD011496 | Pride

Dexamethasone treatment of VCaP prostate cells

Project description:The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. We identified glucocorticoid receptor (GR) activity as modulator of enzalutamite sensitivity in the VCaP prostate cancer cell line. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance whereas a GR antagonist restored sensitivity. These expression profiling data demonstrate that GR transcriptional activity overlaps with that of AR in the VCAP model.

2013-12-27 | GSE51872 | GEO

The estrogen and androgen responses in the immortalized human prostate cancer cell line VCaP

Project description:The aim of the study was to identify the genes regulated by the estrogen receptor alpha (ERa) in a human prostate cancer cell line (VCaP), with and without the co-activation of the oncogene AR (androgen receptor).

2024-04-19 | GSE256370 | GEO

Identification of ZBTB7A cistrome and transcriptome profiles in VCaP prostate cancer cells

Project description:Identification of ZBTB7A cistrome and transcriptome profiles in VCaP prostate cancer cells

| PRJNA507613 | ENA

Dexamethasone treatment of VCaP prostate cells

2013-12-27 | E-GEOD-51872 | biostudies-arrayexpress

Expression profiling of human prostate VCaP and LNCaP cancer cells after silencing ERG or ETV1, respectively

Project description:Chromosomal rearrangements involving ETS factors, ERG and ETV1, occur frequently in prostate cancer. We here examine human prostate cancer cells control VCaP and LNCaP cells with ERG- or ETV1-silenced VCaP or LNCaP cells, respectively, in hormone deprived and stimulated conditions.

2013-03-01 | GSE39354 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data